{"id":45922,"date":"2025-09-25T17:37:06","date_gmt":"2025-09-25T12:07:06","guid":{"rendered":"https:\/\/financialtelegraph.in\/index.php\/2025\/09\/25\/perzea-launch-strengthens-hetero-healthcares-oncology-leadership-through-partnership-with-enzene-biosciences\/"},"modified":"2025-09-25T17:37:06","modified_gmt":"2025-09-25T12:07:06","slug":"perzea-launch-strengthens-hetero-healthcares-oncology-leadership-through-partnership-with-enzene-biosciences","status":"publish","type":"post","link":"https:\/\/financialtelegraph.in\/index.php\/2025\/09\/25\/perzea-launch-strengthens-hetero-healthcares-oncology-leadership-through-partnership-with-enzene-biosciences\/","title":{"rendered":"Perzea Launch Strengthens Hetero Healthcare\u2019s Oncology Leadership Through Partnership with Enzene Biosciences"},"content":{"rendered":"
\n

\"Perzea\"<\/p>\n

Hetero Healthcare and Enzene launched Perzea, India\u2019s most affordable Pertuzumab biosimilar<\/em><\/p>\n

Hyderabad (Telangana) [India], September 25: <\/strong>Hetero Healthcare Limited, in strategic collaboration with Enzene Biosciences, has launched\u00a0Perzea<\/strong>, India\u2019s most affordable\u00a0Pertuzumab biosimilar<\/strong>. The introduction of this targeted therapy for HER2-positive breast cancer demonstrates the synergy between two healthcare leaders committed to\u00a0advanced cancer treatment accessibility<\/strong>.<\/p>\n

Innovation Meets Affordability<\/strong><\/h4>\n

Pertuzumab plays a vital role in the standard of care for HER2-positive breast cancer worldwide. By leveraging Enzene\u2019s patented EnzeneX technology, Perzea becomes not only affordable but also reliable in terms of quality and production efficiency. This innovation-driven partnership sets new standards for biologics in India.<\/p>\n

Speaking on the occasion, Mr. M. Srinivas Reddy, Managing Director of Hetero Healthcare Limited, said:
\n\u201cAt Hetero Healthcare, we believe innovation must be purposeful. With Perzea, we integrate Enzene\u2019s technology with our vision of affordability, ensuring patients in India can access advanced oncology medicines without compromise.<\/strong>\u201d<\/p>\n

Strengthening India\u2019s Biopharma Ecosystem<\/strong><\/h4>\n

The launch of Perzea highlights India\u2019s growing capabilities in biologics manufacturing and biosimilar development. It also reinforces Hetero Healthcare\u2019s dedication to delivering cutting-edge yet cost-effective therapies across oncology and other therapeutic areas.<\/p>\n

About Hetero Healthcare<\/strong><\/h4>\n

Hetero Healthcare Limited is recognised for its wide-ranging portfolio in oncology, critical care, and chronic disease management. The company continues to pioneer initiatives that make\u00a0oncology medicines in India<\/strong>\u00a0more accessible. Visit:\u00a0www.heterohealthcare.com<\/a><\/p>\n

About Enzene Biosciences<\/strong><\/h4>\n

Enzene is a next-generation biologics manufacturer and the first to validate a fully connected continuous manufacturing (FCCM\"\u2122\") platform for commercial biologics supply. Its operations in Pune (India) and New Jersey (USA) focus on biologics innovation and affordability. Visit:\u00a0www.enzene.com<\/a><\/p>\n

Disclaimer:<\/strong> The article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Hetero Healthcare and Enzene launched Perzea, India\u2019s most affordable Pertuzumab biosimilar Hyderabad (Telangana) [India], September 25: Hetero Healthcare Limited, in strategic collaboration with Enzene Biosciences, has launched\u00a0Perzea, India\u2019s most affordable\u00a0Pertuzumab … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":45923,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[99],"tags":[680],"class_list":["post-45922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-health","entry"],"_links":{"self":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/45922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/comments?post=45922"}],"version-history":[{"count":0,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/45922\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media\/45923"}],"wp:attachment":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media?parent=45922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/categories?post=45922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/tags?post=45922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}